<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Allergy, Asthma and Immunology">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>18</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="epublish">
        <Year>2019</Year>
        <Month>08</Month>
        <Day>17</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Skewed X-inactivation in a Female Carrier with X-linked Chronic Granulomatous Disease</title>
    <FirstPage>447</FirstPage>
    <LastPage>451</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Itzel</FirstName>
        <LastName>L&#xF3;pez-Hern&#xE1;ndez</LastName>
        <affiliation locale="en_US">Immunodeficiencies Research Unit, National Institute of Pediatrics, Mexico City, Mexico</affiliation>
      </Author>
      <Author>
        <FirstName>Caroline</FirstName>
        <LastName>Deswarte</LastName>
        <affiliation locale="en_US">Paris Descartes University, Imagine Institute, Paris, France AND&#xA0;Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France</affiliation>
      </Author>
      <Author>
        <FirstName>Miguel &#xC1;ngel</FirstName>
        <LastName>Alcantara-Ortigoza</LastName>
        <affiliation locale="en_US">Department of Genetics, Laboratory of Molecular Biology, National Institute of Pediatrics, Mexico City, Mexico</affiliation>
      </Author>
      <Author>
        <FirstName>Mar&#xED;a del Mar</FirstName>
        <LastName>Saez-de-Ocariz</LastName>
        <affiliation locale="en_US">Department of Dermatology, National Institute of Pediatrics, Mexico City, Mexico</affiliation>
      </Author>
      <Author>
        <FirstName>Marco Antonio</FirstName>
        <LastName>Yamazaki-Nakashimada</LastName>
        <affiliation locale="en_US">Department of Clinical Immunology, National Institute of Pediatrics, Mexico City, Mexico</affiliation>
      </Author>
      <Author>
        <FirstName>Sara Elva</FirstName>
        <LastName>Espinosa-Padilla</LastName>
        <affiliation locale="en_US">Immunodeficiencies Research Unit, National Institute of Pediatrics, Mexico City, Mexico</affiliation>
      </Author>
      <Author>
        <FirstName>Jacinta</FirstName>
        <LastName>Bustamante</LastName>
        <affiliation locale="en_US">Paris Descartes University, Imagine Institute, Paris, France AND St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch,  The Rockefeller University, New York, USA</affiliation>
      </Author>
      <Author>
        <FirstName>Lizbeth</FirstName>
        <LastName>Blancas-Galicia</LastName>
        <affiliation locale="en_US">Immunodeficiencies Research Unit, National Institute of Pediatrics, Mexico City, Mexico</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2019</Year>
        <Month>01</Month>
        <Day>14</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2019</Year>
        <Month>02</Month>
        <Day>12</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by defective phagocytic NADPH oxidase, causing a complete lack or significant decrease in the production of microbicidal reactive oxygen metabolites. It mainly affects male children; however, there are scarce reports of adult females diagnosed with X-linked-CGD attributed to an extremely skewed X-chromosome inactivation. This condition is characterized by severe and recurrent infections that usually develop after childhood. In clinical practice, physicians who usually confront these patients should suspect this entity and differentiate it from a secondary immunodeficiency. Here, we report a 38-year-old Mexican female with juvenile-onset X linked-CGD, caused by a de novo mutation and extremely skewed X-inactivation, whose clinical features were similar to those in patients with classic X-linked-CDG.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2275</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/2275/1432</pdf_url>
  </Article>
</Articles>
